Xbrane Biopharma Logo

Xbrane Biopharma

Develops affordable biosimilars for serious diseases using patented, high-yield production tech.

XBRANE | ST

Overview

Corporate Details

ISIN(s):
SE0007789409 (+1 more)
LEI:
5493008DKD05APTKQO39
Country:
Sweden
Address:
RETZIUS VÄG, 8, 171 65 Solna
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Xbrane Biopharma is a biotechnology company specializing in the development of biosimilars, which are affordable, follow-on versions of approved biological drugs. The company's mission is to increase global access to treatments for serious diseases such as cancer, rheumatoid arthritis, and macular degeneration. Xbrane leverages a patented, high-yield production platform technology designed to significantly reduce manufacturing costs, aiming for up to an 80% cost reduction compared to standard systems. Its development portfolio includes biosimilar candidates targeting major biologic drug markets, such as Xlucane™ (a ranibizumab biosimilar) and BIIB801 (an adalimumab biosimilar).

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 08:00
Share Issue/Capital Change
XBRANE BIOPHARMA AB (“XBRANE” OR THE “COMPANY”) HAS ACCORDING TO PREVIOUSLY ANN…
English 66.6 KB
2025-09-30 08:00
Share Issue/Capital Change
XBRANE BIOPHARMA AB ("XBRANE" ELLER "BOLAGET") HAR ENLIGT TIDIGARE OFFENTLIGGJO…
Swedish 66.6 KB
2025-09-10 08:30
Pre-Annual General Meeting Information
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
English 78.5 KB
2025-09-10 08:30
Pre-Annual General Meeting Information
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Swedish 77.2 KB
2025-08-26 08:00
Interim Report
Swedish 1.3 MB
2025-08-26 08:00
Interim Report
English 1.3 MB
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB ("Xbrane" eller "Bolaget") har enligt tidigare offentliggjo…
Swedish 64.5 KB
2025-07-31 21:00
Share Issue/Capital Change
Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously ann…
English 64.3 KB
2025-07-16 12:24
Major Shareholding Notification
Swedish 10.1 KB
2025-07-11 08:30
Prospectus
Xbrane publishes disclosure document regarding admission to trading of the newl…
English 80.6 KB
2025-07-11 08:30
Share Issue/Capital Change
Xbrane offentliggör undantagsdokument avseende upptagande till handel av de nye…
Swedish 72.9 KB
2025-07-03 11:00
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma i Xbrane Biopharma AB
Swedish 62.1 KB
2025-07-03 11:00
Share Issue/Capital Change
Announcement from extra general meeting in Xbrane Biopharma AB
English 62.4 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
KALLELSE TILL EXTRA BOLAGSSTÄMMA I XBRANE BIOPHARMA AB
Swedish 69.0 KB
2025-06-10 05:15
Pre-Annual General Meeting Information
NOTICE OF EXTRA GENERAL MEETING IN XBRANE BIOPHARMA AB
English 70.2 KB

Automate Your Workflow. Get a real-time feed of all Xbrane Biopharma filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Xbrane Biopharma via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-06-20 Maria Helene Edebrink Other Buy 3,185 210,146.30 SEK
2022-06-16 Siavash Bashiri Other Sell 10,179 675,006.70 SEK
2022-06-16 Karl Martin Erik Åmark Other Sell 5,000 349,150.00 SEK
2022-06-16 Karl Martin Erik Åmark Other Sell 5,000 347,850.00 SEK
2022-06-16 Karl Martin Erik Åmark Other Sell 5,000 347,000.00 SEK
2022-06-16 Maria Helene Edebrink Other Sell 3,185 222,950.00 SEK
2022-06-16 Maria Helene Edebrink Other Buy 1,095 76,321.50 SEK
2022-06-15 Karl Martin Erik Åmark Other Sell 12,000 867,600.00 SEK
2022-06-15 Maria Helene Edebrink Other Sell 1,095 76,650.00 SEK
2022-06-10 Maria Helene Edebrink Other Buy 1,500 103,500.00 SEK

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.